安纳霉素脂质体(Moleculin Biotech)(Annamycin liposomal(Moleculin Biotech)) - 药物靶点：Top II_在研适应症：急性髓性白血病，软组织肉瘤_专利_临床

概要

基本信息

药物类型

小分子化药、脂质体药物

别名-

靶点

Top II

作用机制

Top II抑制剂(拓扑异构酶II抑制剂)

治疗领域

肿瘤血液及淋巴系统疾病其他疾病

在研适应症

急性髓性白血病软组织肉瘤

非在研适应症-

原研机构

Moleculin Biotech, Inc.

在研机构

Moleculin Biotech, Inc.

非在研机构-

最高研发阶段临床2/3期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

7

项与安纳霉素脂质体(Moleculin Biotech) 相关的临床试验

NCT06788756

/ Not yet recruiting临床2/3期

A Pivotal Phase 2/3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Adaptive Design Study of L Annamycin for Injection in Combination with Cytarabine Injection Versus Placebo in Combination with Cytarabine Injection As Second Line Therapy for Remission Induction in Adult Subjects with Refractory/Relapsed Acute Myeloid Leukemia

This pivotal phase 2/3, multi-center, adaptive design study of L-Annamycin for Injection in combination with Cytarabine Injection as second line therapy for remission induction in adult subjects with refractory/relapsed AML is divided into two parts, Part A and Part B.

开始日期2025-01-01

申办/合作机构

Moleculin Biotech, Inc.

NCT05319587

/ Active, not recruiting临床1/2期

Phase 1/2 Study of Liposomal Annamycin in Combination with Cytarabine for the Treatment of Subjects with Acute Myeloid Leukemia (AML)

This is a Phase 1/2, multicenter, open-label, dose-escalation study that will determine the MTD and RP2D of L-Annamycin in combination with cytarabine for the treatment of subjects with AML.

开始日期2022-09-29

申办/合作机构

Moleculin Biotech, Inc.

EUCTR2021-003762-13-PL

/ Not yet recruiting临床1/2期IIT

PHASE 1B/2 STUDY OF LIPOSOMAL ANNAMYCIN (L-ANNAMYCIN) IN PATIENTS WITH PREVIOUSLY TREATED SOFT-TISSUE SARCOMAS WITH METASTASES (ANNA-SARC) - ANNA-SARC

开始日期2022-07-05

申办/合作机构-

100 项与安纳霉素脂质体(Moleculin Biotech) 相关的临床结果

登录后查看更多信息

100 项与安纳霉素脂质体(Moleculin Biotech) 相关的转化医学

登录后查看更多信息

100 项与安纳霉素脂质体(Moleculin Biotech) 相关的专利（医药）

登录后查看更多信息

100 项与安纳霉素脂质体(Moleculin Biotech) 相关的药物交易

登录后查看更多信息